WELCOME

So far, these experiments have produced promising results. But more

Oct. 10, 2018 by Elizabeth Duran

So far, these experiments have produced promising results. But more research is needed, says co-author Tom Fauci, director of the Institute of Biological and Environmental Sciences, at the University of St. Andrews, and one of the researchers who first made the discovery.

It is clear that a broad neutralizing antibody can be useful in many areas of the immune system. We have a variety of different strains that are susceptible to common diseases, like breast and prostate cancer. And, in some cases, it can also be useful in an acute, severe, or life-threatening condition.

"In our case," Fauci says, "we are dealing with a broad neutralizing antibody. The antibody can be used to target a specific pathogen in the body or in the blood or in the brain, or in cells that cause autoimmune diseases such as myocarditis or myocarditis, but also to target a specific specific pathogen."

"In our case," Fauci adds, "we are dealing with a broad neutralizing antibody. The antibody can be used to target a specific pathogen in the body or in the blood or in the brain, or in cells that cause autoimmune diseases such as myocarditis or myocarditis, but also to target a specific specific pathogen."

But it gets easier than it sounds. If Fauci's group developed a broadly neutralizing antibody that would make it possible to block the activity of a large number of flu viruses, we would be able to treat more of the infections that we now have to deal with. And, when we do, it would help us avoid many more of the infections that we have now.

The team's latest work is part of a larger effort that includes Dr. Martin K. Hausner, a gerontologist at Mount Sinai in New York City, and Michael D. R. Schumacher, an immunologist at the University of Rochester in Rochester, N.Y., who are leading the experimental work.